Dyadic and Scripps Partner to Advance Hantavirus Antibodies and Vaccines
Dyadic Applied BioSolutions and Scripps Research Collaborate on Hantavirus Antibodies and Vaccines
Dyadic Applied BioSolutions announced a collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates for hantaviruses using its C1 platform. The partnership aims to leverage Dyadic's C1 microbial platform for rapid development, high-productivity fermentation, and scalable biologic manufacturing.
Key Highlights of the Collaboration
The collaboration will assess monoclonal antibodies and vaccine candidates targeting hantaviruses, including Andes virus. Prior work on Andes, Ebola, and Marburg showed that C1-produced antibodies have comparable binding and neutralization to mammalian systems.
Dyadic and Scripps will pursue external partnerships and non-dilutive funding to support further development. Activities will be conducted through grants and collaborations to validate C1, while Dyadic retains its commercial focus on non-pharma protein products.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…